SEC Comment Letter 0000000000-24-001754 to Intellipharmaceutics International Inc. (IPCIF) (CIK 0001474835)
Intellipharmaceutics International Inc. (IPCIF) (CIK 0001474835)
Date: Feb. 14, 2024 · CIK: 0001474835 · Accession: 0000000000-24-001754
AI Filing Summary & Sentiment
File numbers found in text: 000-53805
Letter
United States securities and exchange commission logo February 14, 2024 Dr. Amina Odidi Acting Chief Financial Officer Intellipharmaceutics International Inc. 30 Worcester Road Toronto, Ontario M9W 5X2 Re:Intellipharmaceutics International Inc. Form 20-F/A for the fiscal year ended November 30, 2022 Filed February 6, 2024 File No. 000-53805 Dear Dr. Amina Odidi: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
February 14, 2024
Dr. Amina Odidi
Acting Chief Financial Officer
Intellipharmaceutics International Inc.
30 Worcester Road
Toronto, Ontario M9W 5X2
Re:Intellipharmaceutics International Inc.
Form 20-F/A for the fiscal year ended November 30, 2022
Filed February 6, 2024
File No. 000-53805
Dear Dr. Amina Odidi:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences